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Abstract: Development of anticancer drugs targeting Aurora B, an important member of 
the serine/threonine kinases family, has been extensively focused on in recent years. In this 
work, by applying an integrated computational method, including comparative molecular 
field  analysis  (CoMFA),  comparative  molecular  similarity  indices  analysis  (CoMSIA), 
homology modeling and molecular docking, we investigated the structural determinants of 
Aurora B inhibitors based on three different series of derivatives of 108 molecules. The 
resultant  optimum  3D-QSAR  models  exhibited  (q
2 = 0.605,  r
2
pred = 0.826),  (q
2 = 0.52, 
r
2
pred = 0.798) and (q
2 = 0.582, r
2
pred = 0.971) for MK-0457, GSK1070916 and SNS-314 
classes, respectively, and the 3D contour maps generated from these models were analyzed 
individually.  The  contour  map  analysis  for  the  MK-0457  model  revealed  the  relative 
importance  of  steric  and  electrostatic  effects  for  Aurora  B  inhibition,  whereas,  the 
electronegative groups with hydrogen bond donating capacity showed a great impact on the 
inhibitory activity for the derivatives of GSK1070916. Additionally, the predictive model 
of  the SNS-314 class revealed the  great  importance of hydrophobic favorable contour, 
since hydrophobic favorable substituents added to this region bind to a deep and narrow 
hydrophobic  pocket  composed  of  residues  that  are  hydrophobic  in  nature  and  thus 
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enhanced  the  inhibitory  activity.  Moreover,  based  on  the  docking  study,  a  further 
comparison of the binding modes was accomplished to identify a set of critical residues 
that play a key role in stabilizing the drug-target interactions. Overall, the high level of 
consistency between the 3D contour maps and the topographical features of binding sites 
led to our identification of several key structural requirements for more potency inhibitors. 
Taken together, the results will serve as a basis for future drug development of inhibitors 
against Aurora B kinase for various tumors.  
Keywords: Aurora B;  drug design; 3D-QSAR; CoMFA; CoMSIA; molecular docking; 
homology modeling 
 
1. Introduction 
The  Aurora  kinases  are  a  family  of  three  highly  homologous  serine-threonine  protein  kinases 
(Aurora A, B and C) that play a critical role in regulating many of the processes that are pivotal to 
mitosis [1]. Since it was discovered that Aurora kinases are aberrantly over-expressed in various tumor 
cells  [2],  there  has  been  intense  research  in  the  area  of  identifying  selective  Aurora  inhibitors  as 
potential drugs; up to now more than 10 small molecules have entered clinical studies [1]. In the last 
decades, compared with Aurora B, Aurora A has received most of the attention in terms of a link with 
human cancers in the field of drug development, since the inhibition of Aurora B could rapidly lead to 
a catastrophic mitosis and cell death, and the inhibition of Aurora B, rather than of Aurora A, is also 
more crucial for the inhibition of cell proliferation [3].  
Aurora  B  is  involved  in  ensuring  chromosome  segregation  and  alignment  as  part  of  the 
chromosomal passenger protein complex (CPC), which plays  a key role  in regulating progression 
through and completion of mitosis [4]. A number of studies  have characterized the gross cellular 
effects  of  disrupting  Aurora  B  in  cells,  including  the  expression  of  kinase  dead  protein,  siRNA 
depletion of total protein, or microinjection of neutralizing antibodies [1]. Some work also showed that 
the depression of Aurora B kinase activity by small inhibitors could lead to a failure in cytokinesis and 
abnormal exit from mitosis, resulting in the endoreduplication, accumulation of polyploidy cells and 
ultimately apoptosis [5–7].  
Encouragingly, series of small molecules have been investigated and exhibited efficient inhibitory 
activities against Aurora B [4,8–10]. MK-0457, the first Aurora inhibitor to enter clinical trials, can 
effectively disrupt mitosis and promote apoptosis in cycling cells while still leaving the non-cycling 
cells  unaffected  [6].
  It  also  possesses  interesting  characteristics  in  that  this  compound  exhibits 
approximately  equal  potency  to  all  three  types  of  Aurora  kinases,  which  definitely  improves  the 
efficiency of the molecule. GSK1070916 [11], a kind of 7-azaindole derivative, is another potent and 
selective  ATP-competitive  inhibitor  of  both  Aurora  B  and  C  with  a  >250-fold  selectivity  over  
Aurora A [9]. Recently, this Aurora B inhibitor was also advanced as an agent for the treatment of 
cancer [12,13]. SNS-314, the third important pan-Aurora inhibitor based on a 4-aminothieno [3,2-d] 
pyrimidine scaffold, attracted much research interest not only due to its good affinity against all three Int. J. Mol. Sci. 2010, 11                       
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isoforms of Aurora kinases [1], but also because of its compelling preclinical profile; it has entered 
clinical trials in patients with solid tumors [4,10].  
Structure-activity analysis is the foundation for understanding the structural features of both the 
inhibitors and the target receptors involved in a particular biological process and thus helps to design 
more effective inhibitors [14]. Therefore, this method has encouraged its wide use as a rational way to 
gain insight into the influence of various interactive fields on the activity and thus to aid in the design 
and forecasting of the inhibitory activity of novel inhibitors [15–21]. In this work, the most widely 
used computational tools, comparative molecular field analysis (CoMFA) and comparative molecular 
similarity indices analysis (CoMSIA) methods [22,23], were used to derive 3D-QSAR models for the 
above  three  different  chemical  series  of  Aurora  B  inhibitors.  Meanwhile,  molecular  docking  was  
also  performed  to  combine  with  the  3D-QSAR  method,  presenting  more  informative  data  for  the  
drug design.  
To date, a number of Aurora B small molecule inhibitors, from structurally diverse chemical series, 
have already been reported or reviewed elsewhere [1,4,8–10]. However, very few series of Aurora B 
inhibitors have so far received much attention from a theoretical perspective. More recently, an elegant 
3D-QSAR work concerning the quinazoline derivatives of AZD1152 and ZM447439 classes combined 
with  molecular  docking  was  reported  [24].  The  authors  found  the  highly  active  ligands  could  be 
designed by varying positively charged, bulky, hydrophobic substitutes at the quinazoline ring, and 
bulky and hydrophobic groups around the thiazole ring were desirable for higher activity [24]. More 
recently, several other series of compounds, such as MK-0457 [8], GSK1070916 [9] and SNS-314 [4] 
derivatives, have been reported as promising Aurora B inhibitors. However, no comprehensive features 
of the ligand-receptor interactions or detailed structural determinants at the atomic level were obtained 
for these inhibitors since the X-ray crystallographic structure for the human Aurora B kinase has not 
been reported to date. Therefore, in the present study, we mainly focus on the study of the above three 
classes of inhibitors with an attempt to disclose the structural features of anticancer Aurora B inhibitors 
using an integrated computational method including 3D-QSAR, homology modeling and molecular 
docking simulations. A comparison was also performed to identify similarities and differences in the 
binding modes for each class, and thus a set of vital amino acid residues were found to play a critical 
role in stabilizing the ligand-receptor interactions of Aurora B kinase. To our knowledge, this work 
presents the first 3D-QSAR study for these series of compounds, which will provide a platform for the 
screening and design of novel Aurora B inhibitors as important weapons in the fight against tumors.  
2. Materials and Methods  
2.1. Data Sets  
All  molecules  used  as  Aurora  B  inhibitors  in  the  present  study  have  been  collected  from  the 
literature recently published [4,8–10]. Discarding compounds with unspecified inhibitory activity, the 
data set used comprises series of diverse MK-0457, GSK1070916, SNS-314 derivatives, which have 
been shown to possess a wide spectrum of inhibitory activities against Aurora B enzyme. The three 
different  groups  of  compounds  were  assayed  for  their  Aurora  B  inhibitory  activity  by  using  the 
standard coupled enzyme assay [8], the human lung cancer cell line A549 [9], the humanized mouse Int. J. Mol. Sci. 2010, 11                       
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Aurora enzyme [10], Aurora B enzymatic assay and a BrdU cell proliferation assay [4]. The in vitro 
biological activities Ki (μM) and the IC50 values (μM) were converted into the corresponding inhibitory 
activity pKi (−logKi) and pIC50 (−logIC50) values as dependent variables in deriving the QSAR models. 
Since the 3D-QSAR models were generated from training set molecules and further confirmed using 
an external test set, each group was divided into two sets, consisting of training and tested compounds. 
The test set was selected in such a way that the experimental values are almost uniformly distributed in 
the range of the values for the whole set. The structures and inhibitory activity data of representative 
compounds  in  the  training  and  test  sets  are  given  in  Tables  1–3.  (All  the  chemicals  with  their 
structures, biological values, and their division into the training and test sets are listed in the supporting 
information). 
2.2. Molecular Modeling 
All the 3D-QSAR and molecular docking computations were performed using Sybyl (Tripos, Inc.) 
[25].  The  3D  structures  of  molecules  were  built  using  the  Sketch  Molecule  function  with  Sybyl 
software. The geometry optimizations of all compounds were carried out by using the TRIPOS force 
field  with  the  Gasteiger  Huckel  charges,  and  repeated  minimization  was  performed  using  Powell 
conjugated gradient algorithm method until the root-mean-square (rms) deviation of 0.001 kcal/mol 
was achieved. In the present study, the most potent molecule of each class (compounds 25, 40, 105, 
respectively) was chosen as a template to fit the remaining compounds in the training and test sets 
through the fit atoms function in SYBYL. Thus, all compounds finally minimized with the lowest 
energy in the data set were aligned to a common substructure by substructure-based alignment method 
using  the  “align  database”  command  in  SYBYL.  The  determined  common  substructures  for  the 
alignment are shown in bold face. (See Tables 1–3).  
Table 1. Representative skeletons and molecular structures of MK-0457 derivatives and 
their binding affinity values (pKi).  
 
Compound  Template  R1  Ar  pKi (μM) 
8  a  Me  4-(NHSO2Me)Ph  0.638 
9  a  Me  4-(NHC(O)OtBu)Ph  0.602 
11  a  Me  4-(NMeC(O)Me)Ph  0.979 
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Table 1. Cont.  
Compound  Template  R2  R3  pKi (μM) 
18  b  Me  Et  0.815 
19
a  b  CyPr  Et  1.229 
20
a  b  tBu  Et  0.939 
21  b  Ph  Et  0.839 
22  b  3-Py  Et  1.284 
23  b  4-Py  Et  1.310 
24  b 
 
Et  1.638 
25  b 
 
Et  2.097 
26  b 
 
Et  1.854 
27  b 
 
Et  1.745 
28  b 
 
Et  1.699 
29
a  b 
 
Et  1.602 
30
a  b 
 
Et  2.022 
31  b 
 
Et  1.959 
a Test set molecules. The common structure for molecular alignment is shown in bold face. 
Table 2. Representative skeletons and molecular structures of GSK1070916 derivatives 
and their binding affinity values (pIC50).  
 
Compound  Template  R1  pIC50 (μM) 
35
b  c  Et  2.699 
40  c 
 
3.000 
41  c    2.699 Int. J. Mol. Sci. 2010, 11                       
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Table 2. Cont. 
Compound  Template  R2  pIC50 (μM) 
48  d 
 
1.699 
52  d 
 
1.959 
53  d 
 
1.244 
54  d 
 
1.180 
55  d 
 
2.301 
57  d 
 
2.301 
62  d 
 
1.658 
63  d 
 
1.081 
Compound  Template  R2  R3  pIC50 (μM) 
65  e 
   
2.523 
66  e 
   
2.301 
67  e 
   
2.770 
68  e 
   
2.444 
69  e 
   
2.854 
70  e 
   
2.678 
71
a  e 
   
2.824 
72  e 
   
2.347 
75  e 
   
2.328 
76  e 
   
2.092 
a Test set molecules, 
b Outliers. The common structure for molecular alignment is shown in bold face. Int. J. Mol. Sci. 2010, 11                       
 
 
4332 
Table 3. Representative skeletons and molecular structures of sns-314 derivatives and their 
binding affinity values (pIC50).  
 
Compound  Template  R1  pIC50 (μM) 
80  f  –Ph  0.921 
82  f  3–F–C6H4  1.745 
88  f 
 
1.658 
89
a  f 
 
0.921 
Compound  Template  X  Y  U  R3  pIC50 (μM) 
94  g  CH  NH  CH  H  2.000 
97  g  CH  NMe  CH  H  0.553 
98  g  CH  O  CH  H  0.921 
99  g  CH  S  CH  H  −0.398 
103
b  g  N  NH  CH  CF3  1.201 
105  g  CH  NH  N  CF3  2.301 
a Test set molecules, 
b Outliers. The common structure for molecular alignment is shown in bold face. 
2.3. 3D-QSAR Analysis 
To derive the CoMFA and CoMSIA descriptor fields, a 3D cubic lattice with grid spacing of 2 Å in 
x,  y,  and  z  directions,  was  finally  generated  to  encompass  the  aligned  molecules.  In  CoMFA, 
descriptors of steric and electrostatic fields were calculated using an sp
3 carbon probe atom with a van 
der Waals radius of 1.52 Å and a charge of 1.0 to generate energies for both the steric and electrostatic 
fields with a distance-dependent dielectric at each lattice point. Energy values for both steric and 
electrostatic fields were truncated at a default energy cut-off value of 30 kcal/mol. The CoMFA steric 
and  electrostatic  fields  generated  were  automatically  scaled  using  the  CoMFA-STD  method  in 
SYBYL. Another 3D QSAR procedure, CoMSIA, involving a common probe atom and similarity 
indices calculated at regularly spaced grid intervals for the prealigned molecules, were derived with the 
same lattice box implemented in SYBYL as that used for the CoMFA calculations. In addition to steric 
and  electrostatic  fields,  hydrophobic,  and  hydrogen-bond  donor  and  acceptor  descriptors  were 
calculated with the same lattice box of a regularly placed grid of 2.0 Å, employing a probe atom with 
radius 1.0 Å, charge 1.0, and hydrophobicity +1.0. CoMSIA similarity indices (AF) for a molecule j 
with atoms i at a grid point q were calculated by Equation (1): 
2 F,K probe, ()
r q
k ik iq A j e



   (1) Int. J. Mol. Sci. 2010, 11                       
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where k represents the steric, electrostatic, hydrophobic, hydrogen-bond donor or hydrogen-bond-acceptor 
descriptor. Compared to the CoMFA approach, which has two fields, in the CoMSIA method, five 
physico-chemical  properties  were  associated,  including  three  additional  properties  of  hydrophobic, 
hydrogen  bond  donor  and  hydrogen  bond  acceptor,  which  were  evaluated  using  the  common  sp
3 
carbon probe atom. Meanwhile, a default value of 0.3 was used as the attenuation factor and a distance 
dependent Guassian type functional form has been used between the grid point q and each atom i in the 
molecule. This can avoid singularities at the atomic positions and the dramatic changes of potential 
energy due to grids in the proximity of the surface [26].  
In  the  partial-least-squares  (PLS)  analysis,  the  CoMFA  and  CoMSIA  descriptors  served  as 
independent  variables  and  the  pIC50  or  pKi  (μM)  values  served  as  dependent  variables  to  deduce  
3D-QSAR  models  [27–31].  The  predictive  capabilities  of  the  models  were  first  evaluated  in  
leave-one-out (LOO) cross validation method. The number of components  resulting in the highest 
cross-validated  r
2  and  lowest  standard  error  of  prediction  (SEP)  was  determined  as  the  optimum 
number of principal components (Nc) in the ﬁnal PLS analyses. The predictive rpred
2 based on molecules 
in the test set was calculated to evaluate the predictive power of the CoMFA and CoMSIA models using 
Equation (2): 
2
pred ( )/ r SD PRESS SD    (2) 
where SD is the sum of the squared deviations between the actual activities of the molecules in the test 
set and the mean activity of the molecules in the training set, and PRESS is the sum of the squared 
deviations between the predicted and the actual activity values of every molecule in the test set.  
2.4. Homology Modeling 
Homology modeling procedures are indispensable tools for conducting research involving structure 
based drug design when the experimental 3D-structure of the receptor is not available [32]. In the 
present  study,  due  to  the  unavailability  of  Aurora  B  X-ray  crystallographic  structure  for  humans, 
homology modeling process was employed as a theoretical method to predict the protein structure 
from the target amino acid sequence (accession BC000442) obtained from the National Center for 
Biotechnology Information database (http://www.ncbi.nlm.nih.gov). The homology model of Aurora B 
was built based on sequence alignment and the obtained target amino acid sequence was submitted to 
SWISS-MODEL  server  (Automated  Comparative  Protein  Modeling  Server,  Version  3.5, 
GlaxoWellcome Experiment Research, Geneva, Switzerland, http://swissmodel.expasy.org) [33,34] for 
a comparative structural modeling. Meanwhile, the template protein (PDB code 2BFX chain A from 
Protein  Data  Bank  http://www.rcsb.org),  which  exhibits  a  high  resolution  (1.8 Å),  was  employed  
to  generate  the  3D  protein  structure.  All  hydrogen  atoms  were  subsequently  added  to  the  
unoccupied valence of heavy atoms at the corresponding neutral state using the biopolymer module of  
SYBYL package.  
2.5. Molecular Docking 
To explore the interaction and illustrate the accurate binding model for the active site of Aurora B 
with its ligands, molecular docking analysis was carried out by using the Surflex Dock implemented in Int. J. Mol. Sci. 2010, 11                       
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SYBYL. Meanwhile, the resulting homology protein structure for docking was further developed using 
the protein preparation and reﬁnement utility provided by SYBYL. Finally, each conformer of all 108 
inhibitors in three different groups was docked into the binding site 10 times. Prior to docking analysis, 
in order to assure the quality of the binding mode of the ligands and reproduce the proper X-ray 
structure, the following  criteria were  applied to perform molecular  docking  analysis:  (1) The  key 
residues like Glu161 and Ala157, as major contributors to the enhanced affinity [35], should well bind 
to ligand; (2) the most potent inhibitors (compounds 25, 40 and 105) should have similar binding poses 
in the active site and the top ranked docked solution in one favorable cluster of docking poses meets 
satisfying root-mean-square deviation (RMSD) values; (3) the putative poses of the potent compounds 
were also  scored using  the Hammerhead scoring function [36], which also  serves  as  an objective 
function  for  local  optimization  of  poses.  Additionally,  two  parameters,  i.e.,  protomol_bloat  and 
protomol_threshold, which determine how far from a potential ligand the site should extend and how 
deep into the protein the atomic probes used to define the protomol can penetrate, are specified 1_0.55, 
0_0.66 and 0_0.75 for each group, respectively. 
3. Results and Discussion  
3.1. CoMFA and CoMSIA Statistical Results 
In order to develop an effective model with good prediction, a number of parameters, such as the 
cross-validated  correlation  coefficient  (r
2
cv),  non-cross-validated  correlation  coefficient  (r
2
ncv), 
standard  error  estimate  (SEE)  and  F-statistic  values  were  taken  into  consideration.  For  all  of  the  
3D-QSAR  models,  the  LOO  cross-validation  was  performed  first  to  identify  the  cross-validated 
correlation  coefficient  (q
2)  values.  Then  the  number  of  components  identified  in  the  LOO  
cross-validation process was used in the final non-cross-validated PLS run. Generally, a q
2 value of 
greater than 0.5 is usually considered significant. To further assess the stability and confidence of the 
derived  CoMFA  and  CoMSIA  models,  bootstrapping  analysis  for  100  runs  was  applied  to  the 
compounds of the training set. In CoMSIA, five descriptors (steric, electrostatic, hydrophobic, and 
hydrogen-bond-donor and hydrogen-bond-acceptor) are available to be considered. But it has been 
established  that  the  five  different  descriptor  fields  are  not  totally  independent  of  each  other  and  
that  such  dependency  among  individual  field  usually  decrease  the  statistical  significance  of  the  
models [37]. For this reason, all 31 possible descriptors’ combinations for each group were calculated 
with purpose to build the optimal 3D-QSAR models with the highest q
2 values and other statistical 
results for each class. Table 4 summarizes the statistical results of the optimum model for each class, 
and for the modeling results of the other 93 combinations of CoMFA or CoMSIA descriptors, see 
Tables S7–S9 in supporting information.  
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Table 4. Summary of statistics and field contributions for the top model of each class. 
Parameters 
MK-0457  GSK1070916  SNS-314 
CoMSIA  CoMSIA  CoMSIA 
Q
2 a  0.605  0.52  0.582 
R
2
ncv 
b  0.882  0.904  0.889 
SEE 
c  0.232  0.215  0.295 
F 
d  50.159  65.993  28.832 
R
2
pred 
e  0.826  0.798  0.971 
SEP 
f  0.410  0.482  0.572 
PLS components 
g  3  4  5 
R
2
boot 
h  0.930  0.936  0.921 
SDboot 
i  0.028  0.023  0.032 
SEEboot 
j  0.174  0.172  0.245 
Field contribution 
Steric  0.323  -  - 
Electrostatic  0.677  0.69  - 
Hydrophobic  -  -  0.607 
Hydrogen-bond-donor  -  0.31  0.393 
a Cross-validated correlation coefficient after the leave-one-out procedure; 
b Non-cross-validated 
correlation  coefficient; 
c  Standard  error  of  estimate; 
d  Ratio  of  R
2
ncv  explained  to  
unexplained = R
2
ncv/(1−R
2
ncv); 
e Predicted correlation coefficient for the test set of compounds;  
f Standard error of prediction. 
g Optimal number of principal components; 
h Average of correlation 
coefficient for a total of 100 runs of bootstrap analysis; 
i Standard deviation of average bootstrap 
analysis correlation coefficient for 100 runs;
 j Average standard error of estimate for a total of 100 
runs of bootstrap analysis. 
3.2. Validation of the 3D QSAR Models 
Statistically significant CoMFA and CoMSIA models were derived from the training compounds 
and further used to predict test molecules. The resultant optimum models exhibited agreeable statistical 
results  of  (q
2 = 0.605,  r
2
pred = 0.826),  (q
2 = 0.52,  r
2
pred = 0.798)  and  (q
2 = 0.582,  r
2
pred = 0.971)  for  
MK-0457, GSK1070916 and SNS-314 classes, respectively (Table 4), and relatively small prediction 
errors (<−0.098, 0.044 and 0.038, see Supporting Information). The experimental versus predicted 
activities are shown in Figure 1, through which we can find that all the training and test compounds are 
well distributed around the regression lines, indicating that the obtained CoMFA/CoMSIA models 
presented good performance on both the training and test compounds. 
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Figure 1. The correlation plots of predicted versus actual Aurora B inhibitory activities 
using the training (white squares) and test (black triangles) sets based on (A) CoMSIA 
model  of  MK-0457;  (B)  CoMSIA  model  of  GSK1070916  and  (C)  CoMSIA  model  of  
SNS-314. The solid lines are the regression lines for the fitted and predicted bioactivities of 
training and test compounds in each class, respectively. 
 
3.2.1. MK-0457 
The 3D-QSAR models were generated from MK-0457 derivatives with pKi (μM) values ranging 
from 0.002 to 2.097 (24 training and 8 test compounds). The statistical results of the optimal model are 
in Table 4. Satisfyingly, most of the 31 models derived from various combinations of fields present 
high predictive r
2
cv values (>0.5). (See Supporting Information). The optimal CoMSIA model yielded 
r
2
cv = 0.605 with 3 components, r
2
ncv = 0.882, r
2
pred = 0.826 and the respective steric and electrostatic 
field contributions of 33% and 67%. And the best CoMFA model also presented reasonable statistical 
features with r
2
cv = 0.604, 8 components, r
2
ncv = 0.992, r
2
pred = 0.692, steric 62% and electrostatic 38% 
field contributions. Overall, the performance of the CoMSIA model is superior to that of the CoMFA 
one. Meanwhile, an incorporation of the hydrogen-bond donor/acceptor or both fields yielded makes 
the models perform poorer, suggesting the steric and electrostatic fields were statistically robust in 
building the models. 
3.2.2. GSK1070916 
Table 4 summarizes the statistical parameters of the optimal model for GSK1070916 compunds. A 
combination  of  steric  and  electrostatic  fields  produced  poor  CoMFA  and  CoMSIA  models  with 
internal predictions of r
2
cv = 0.295 and 0.178, respectively. While, incorporation of the hydrogen-bond 
donor/acceptor or both fields could improve the model performance, thus the optimal CoMSIA model 
generated  with  these  fields  showed  a  reasonable  r
2
cv = 0.52  with  4  components,  r
2
ncv = 0.904, 
r
2
pred = 0.798 and higher electrostatic field contribution (69%) than hydrogen-bond-donor (31%) field. 
Meanwhile,  the  models  derived  from  the  combinations  of  SDA  (steric,  hydrogen-bond  donor  and 
acceptor  fields)  and  HDA  (hydrophobic,  hydrogen-bond  donor  and  acceptor  fields)  showed 
comparable predictions. However, both of them were not accepted as they applied more number of the 
components (up to 9). The 3D contours analyzed for the generated model are shown in Figure 4 (A, B). Int. J. Mol. Sci. 2010, 11                       
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In building the models, compound 35 was treated as an outlier, because including this compound 
the optimal models yielded a high residual value of more than 1 logarithm unit. In addition, the PLS 
analysis  on  alignment  of  all  the  compounds  resulted  in  modest  r
2
cv  values  (averagely < 0.30), 
indicating possible outlier exists in this data set. This outlier might be due to experimental errors since 
this compound has a similar functional group in –R3 group with those less active compounds, such as 
48, 52, 53 and 54, while this compound has a high pIC50 value.  
3.2.3. SNS-314 
Selective SNS-314 Aurora B inhibitors with IC50 (μM) values ranging from 0.005 to 5.600 were 
used to generate 3D-QSAR models (24 training and 7 test compounds). Although these compounds 
were retrieved from two independent publications [4,10], three common compounds (77, 80 and 83) 
were found to be in both literatures with exactly the same biological activities, which further validates 
the feasibility of utilizing the multi-source data. The statistical parameters of the optimal model are 
shown in Table 4. The CoMFA model showed poor internal predictions (r
2
cv = 0.079) using steric and 
electrostatic  fields,  which  is  also  true  for  the  CoMSIA  model.  However,  the  models  using  a 
combination of SEHD could improve the model performance (r
2
cv = 0.069–0.430, r
2
ncv = 0.555–0.716 
and  r
2
pred = 0.806–0.937).  And  the  model  obtained  with  combination  of  hydrophobic  and  
hydrogen-bond  donor  fields  showed  highest  r
2
cv = 0.582,  r
2
pred = 0.971,  r
2
ncv = 0.910  and  the 
corresponding contributions of hydrophobic and hydrogen-bond-donor fields of 60.7% and 39.3%. 
Therefore, this model was further used to analyze 3D contour plots in Figure 5 (A, B). 
Compound  107 was  eliminated in  building  the models,  as the best  model  with  this  compound 
produced a modest r
2
cv value of 0.385. Omission of this resulted in a great increase in r
2
cv value to 
0.582. The outlier status of compound 107 could stem from its structural uniqueness, when compared 
to its counterparts, compounds 94–106.  
3.3. Homology Modeling  
The initial sequence alignment between the target (Aurora B kinase for humans) and the template 
(PDB code: 2BFX) sequences is shown in Figure 2A. The whole sequence identity between the target 
and the template protein  is  80.6% and therefore, we  conclude that this alignment  can be used to 
construct a reliable 3D model [38]. Additionally, besides the insertions and deletions detected in the 
loop regions corresponding to the functional regions of Gly loop (amino acids 81–93), catalytic cleft 
(amino  acids  154–161)  and  activation  loop  (amino  acids  80–220)  [35],  there  is  only  one  single 
replacement detected in the catalytic cleft and two in the activation loop region, and thus the identity of 
the functional region is as high as 85.0%. The superposition of the two 3D structures is shown in 
Figure  S1,  indicating  that  the  overall  conformation  of  the  modeling  target  is  very  similar  to  the 
template with a root-mean-square deviation (RMSD) of 0.078 Å. In addition, our alignment was also 
carefully checked in the key residues of binding site (highlighted in black rectangles) where it was 
found that all critical amino acids (such as Leu83, Lys106, Glu125, Ala157, Glu161 and Asp218) were 
well overlaid in 3D space in the two structures (Figure 2B). 
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Figure 2. (A) The alignments of the sequences of 2BFX chain A template and Aurora B 
target protein. The identical amino acid residues in the sequence alignment are highlighted 
in cyan. Dashed lines denote the amino acid residues deletion. The key residues of binding 
site are highlighted in black rectangles; (B) The enlargement of the superposition structure 
of the active site with compound 40 displayed in sticks. The residues from the template 
protein  and  the  homology  modeling  protein  are  highlighted  in  green  and  red  colors 
respectively,  the  same  residues  in  the  active  site  are  labeled  in  blue  color,  while  the 
residues differing between them are labeled in their own color.  
 
3.4. Validation of the Docking Protocol 
Docking calculations were used to find the optimal conformation of the ligand in the binding pocket 
of Aurora B protein. The top ranked docked solution of each group was found in one favorable cluster 
of docking poses with an average RMSD value 0.61 Å, 0.03 Å and 1.37 Å, respectively, demonstrating 
the binding mode is correctly reproduced. Additionally, the putative poses of the potent compounds 
were scored using the Hammerhead scoring function, which serves as an objective function for local 
optimization of poses. During this docking process, the protein was considered to be rigid, while the 
ligands flexible. By this process, we found that the binding modes for the most potent compounds of 
each class presented statistically significant total score results of 5.89, 6.19 and 4.98, respectively. The 
most active inhibitors of each group have been nicely docked to the active site and the docked models 
(compounds 25, 40 and 105) are shown in Figures 3C, 4C and 5C, respectively. 
3.5. 3D-QSAR Contour Maps and Molecular Docking Correlation  
3.5.1. MK-0457 
The steric and electrostatic fields of CoMSIA are depicted in Figure 3 (A, B). Compound 25, the 
most potent inhibitor in this series,  was overlaid as  a reference structure on the maps. The steric 
contour map showed a green region at –R2 group and this substituent partially extended outside the 
binding pocket (shown in Figure 3C), indicating the requirement of bulky substituents in this region 
for a potent Auora B inhibitor. This may account for the qualitative SAR observation that compounds 
24–31, with the introduction of heterocycles as the 6-substituent on the pyrimidine, had an inhibitory 
improvement against Aurora B [8]. Therefore the low potency of compounds (18, 19 and 20) can be 
explained as they have much smaller groups, such as methyl, cyclo-propyl, tert-butyl, respectively. Int. J. Mol. Sci. 2010, 11                       
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Meanwhile, a sterically disfavored yellow contour is present at the –R3 group, which strongly delimits 
the sideward relocatability. Interestingly, the docking study lends further support to the concept that 
this area was occupied by the residues of Glu161 and Tyr163, indicating that bulky substituents at this 
position will conflict  with  these residues and decrease the activity (shown in  Figure 3C). This  is 
reflected in  compounds 8, 9 and 11, which have bulky substituents (–NHSO2Me, –NHC(O)OtBu,  
–NMeC(O)Me),  respectively,  at  this  position  with  pKi  values  below  1.  This  can  serve  as  an 
explanation for the higher activities of compounds 24–31, who have more bulky substituents in the 
green regions and less bulky substituents in the yellow regions.  
Figure 3. CoMSIA StDev*Coeff contour plots for MK-0457. (A) The steric (green/yellow) 
contour  map  represents  respective  95%  and  5%  level  contribution  combined  with 
compound 25. Green contours indicate regions where bulky substituents increase activity; 
yellow  contours  indicate  regions  where  bulky  substituents  decrease  activity;  (B)  The 
electrostatic (red/blue) contour map represents respective 75% and 25% level contribution 
combined  with  compound  25.  Red  contours  indicate  regions  where  negative  charged 
substituents  increase  activity;  blue  contours  indicate  regions  where  positive  charged 
substituents increase activity; (C) The enlargement for stereoview of the docking structure 
of compound 25 in complex to the active site of the monomer structure of the Aurora B. 
Hydrogen  bonds  are  shown  as  dotted  green  lines.  Active  site  amino  acid  residues  are 
represented as sticks, while the inhibitor is shown as ball and stick model. 
 
For the electrostatic contour maps shown in Figure 3B, positive charges favored regions depicted by 
blue are found on both sides of the –R2 group, suggesting that positive charged groups are appreciated 
here. Therefore, it can be explained that the presence of the residues Ala157 and Glu161 observed 
appearing adjacent to these regions. Another blue contour observed beside the –R2 group may possibly 
account for the low activity of compounds 8, 9, which have substituents of –SO2– and –C(O)O–, 
respectively, right  in  the blue region.  In addition,  a red contour at  atom N of the  piperidine ring Int. J. Mol. Sci. 2010, 11                       
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suggests  that  a  negative  charged  substituent  at  this  position  will  enhance  inhibitory  potency.  A 
comparison of compounds 25 and 21–23 shows that a change from a carbon atom to a nitrogen atom  
of the aromatic ring greatly increases the potency, which may be due to a negative charge increase at  
this position. 
3.5.2. GSK1070916 
The graphical representation for the CoMSIA model from electrostatic and hydrogen-bond donor 
fields is depicted in Figure 4 (A, B). Compound 40 was applied as a reference. The blue contour 
completely enclosed the phenyl ring which specifies that positively charged substitutents in this region 
may increase the activity. This is consistent with the docking study that the phenyl ring is surrounded 
by the amino acids Gln129, Glu125 and Asp218. 
Figure  4. CoMSIA StDev*Coeff contour plots for GSK1070916. (A) The electrostatic 
contour map (red/blue) represents respective 80% and 20% level contribution combined 
with  compound  40. Red  contours  indicate  regions  where  negative  charged  substituents 
increase  activity;  blue  contours  indicate  regions  where  positive  charged  substituents 
increase  activity;  (B)  The  hydrogen-bond  donor  (cyan/purple)  contour  map  represents 
respective 80% and 20% level contribution combined with compound 40. Cyan contours 
indicate  regions  where  hydrogen-bond-donor  favorable  substituents  increase  activity; 
purple  contours  indicate  regions  where  hydrogen-bond-donor  unfavorable  substituents 
decrease  activity;  (C)  The  enlargement  for  stereoview  of  the  docking  structure  of 
compound 40 in complex to the active site of the monomer structure of the Aurora B. 
Hydrogen  bonds  are  shown  as  dotted  green  lines.  Active  site  amino  acid  residues  are 
represented as sticks, while the inhibitor is shown as ball and stick model.  
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The medium size red-colored contour located reside the pyrrole ring indicates the significance of 
less positive charged substituents in this region. Considering compounds 55, 57, 62, 63, both the two 
molecules of 55, 62 as well as 57, 63 have the same structures except at the 1-position of –R2 group. 
The reason for the difference in activities is attributed to the extra carbonyl substituents of compounds 
55 and 57 at this position. Therefore, enhanced activity might be obtained if a negatively charged 
group is added to this position. The CoMSIA contour map for electrostatic field also has a red contour 
enclosing  the  –NH–  at  the  2-position  of  –R3  group,  which  indicates  that  the  negative  charged 
substituents are preferred for higher activity. Meanwhile, a cyan contour of hydrogen-bond-donor field 
located at the same position suggests the structural requirement for hydrogen-bond-donor favorable 
substituents. These findings point to the need for electronegative groups with hydrogen bond donating 
capacity, such as –NH–, which will probably increase the biological activity. Furthermore, this is also 
consistently reflected in the docking study shown in Figure 4C; the –NH– playing a key role as a 
hydrogen bond donor was involved in hydrogen bonding interactions with the backbone of Asp218 
(2.73 Å, 122.6°  and 2.54 Å, 135° ). Similarly, both the red and cyan small contours were observed 
appearing adjacent to the hydroxyl of –R1 group, thus suggesting that a negatively charged substituent 
with hydrogen bond donating capacity added to this position would engage in interactions with the 
receptor and enhance the inhibitory activity. As expected, Ala157 amino residue was found to form 
strong hydrogen bond contacts with the hydroxyl of compound 40 (1.80 Å, 142.5°  and 2.10 Å, 157.2° ). 
Consequently,  hydroxyl  of  –R1  group  appears  to  plays  an  important  role  in  stabilizing  the  
ligand-receptor interactions. Moreover, these findings further support the putative binding mode of the 
initial structure-activity relationship study that the pyrazole ring occupies the sugar pocket region of 
the ATP-binding site [14]. Therefore, this may possibly account for the high Aurora B inhibitory 
activity of compounds 39, 40 and 41, which have incorporated polar hydrogen bond donating groups  
(–OH) forming hydrogen bonds with Ala157 residue to enhance the potency. 
3.5.3. SNS-314  
Figure  5  provides  the  graphical  representation  for  the  CoMSIA  model  using  hydrophobic  and 
hydrogen-bond donor fields, with compound 105 as the template. The yellow contour at the –R3 group 
suggests  that  substituents  added  here  desired  a  favorable  hydrophobic  interactions  with  the  target 
receptor. This is consistent with the docking study that most of the amino acid residues near the yellow 
contour regions are hydrophobic in nature (e.g. Val, Ala and Leu). As depicted in Figure 5C, the 
substituent (–CF3) at the –R3 group is placed in the hydrophobic pocket formed by Leu154, Leu138, 
Val91, Ala104, and Ala217. Thus, this can be expected to explain the correspondingly lower activities 
of  compounds  80  and  89.  In  contrast,  compounds  82  and  88  that  have  groups  with  high 
hydrophobicity,  such  as  –CF3 and  –F,  at  the  –R3  group  of  the  aromatic  ring  are  distinctly  more  
active  [4].  Another  small  yellow  contour  observed  close  to  the  meta-position  of  the  phenyl  ring 
indicates  that  hydrophobically  favored  substituents  connected  to  this  position  will  enhance  the 
biological activity. For example, the structure of compound 100 has an N atom at meta-position of the 
phenyl  ring,  while  compound  103  has  a C  atom  in  the  opposite  and thus  shows  a  distinctly  less 
inhibitory activity than  compound  100. Meanwhile, the white  contour  observed  encompassing  the 
imidazole ring moiety indicates the significance of hydrophilic substituents here. This is in agreement Int. J. Mol. Sci. 2010, 11                       
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with  the  experimental  observation  that  compounds  97–99  with  more  hydrophobic  substituents  of  
–NMe–,  –O–,  –S–,  respectively,  in  this  region  have  a  lower  activity  than  compound  94.  The 
reasonably higher inhibitory activity of compound 94 is probably due to occupancy of –NH–, which  
is  placed  in  the  white  contour  and  forms  hydrogen  bond  with  residue  identified  as  Ala157  
(2.03 Å, 162.5° ). A small cyan contour seen distantly located from the –NH of the imidazole ring 
suggests occupancy of this spatial region by a hydrogen bond donor group for a strong inhibitory 
activity. This may be due to the involvement of Ala157 which plays a major role as a hydrogen bond 
acceptor during the interaction with target. A medium size purple contour map seen under the phenyl 
ring indicates that the region is preferred to hydrogen bond acceptor groups. And this observation is 
also consistent with our previous docking study that indicated that –NH of the Gly160 residue acting 
as a hydrogen-bond donor at this area would create desirable close contact between the receptor and 
the ligand as shown in Figure 5C. 
Figure 5. CoMSIA StDev*Coeff contour plots for SNS-314. (A) The hydrophobic contour 
map (yellow/white) represents respective 80% and 20% level contribution combined with 
compound  105.  Yellow  contours  indicate  regions  where  hydrophobic  favorable 
substituents  increase  activity;  white  contours  indicate  regions  where  hydrophobic 
unfavorable  substituents  increase  activity;  (B)  The  hydrogen-bond  donor  (cyan/purple) 
contour  map  represents  respective  85%  and  15%  level  contribution  combined  with 
compound  105.  Cyan  contours  indicate  regions  where  hydrogen-bond-donor  favorable 
substituents increase activity; purple contours indicate regions where hydrogen-bond-donor 
unfavorable  substituents  decrease  activity;  (C)  The  enlargement  for  stereoview  of  the 
docking structure of compound 105 in complex to the active site of the monomer structure 
of the Aurora B. Hydrogen bonds are shown as dotted green lines. Active site amino acid 
residues are represented as sticks, while the inhibitor is shown as ball and stick model.  
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3.6. Comparison of Binding Modes for Each Class 
In order to get a better understanding of the variations in biological activities, we compared the 
binding modes of each group seeking to explore their similarities and differences. Our docked models 
revealed  that  hydrogen  bonding  is  an  important  interaction  between  the  inhibitor  and  the  target 
receptor.  According  to  the  docking  study,  a  total  of  five  hydrogen  bonds  were  formed  between 
compound 25 and residues Lys106 (2.32 Å, 153.8° ; 2.65 Å, 117.2° ; 2.58 Å, 114.8° ), Ala217 (2.92 Å, 
101.5° ), and Glu125 (3.28 Å, 160.2° ) of the target receptor (Figure 3C). Interestingly, the common 
structure of MK-0457 derivatives was found to form a total of five key hydrogen bonding interactions 
with the receptor. Therefore, this further supports the evidence of its essential role for the overall 
inhibitory activity. Furthermore, Ala157 and Glu161 residues were also found to possess important 
electrostatic repulsion interactions with the ligand. Additionally, for the derivatives of GSK1070916, 
eight hydrogen bonds were uncovered during the docking procedure. Amino acids of Lys106 (1.87 Å, 
129.6° ; 2.79 Å, 110° ; 2.91 Å, 119.8° ), and Asp218 (2.08 Å, 150.3° ; 2.54 Å, 135° ) appeared to have 
hydrogen bonding interactions with compound 40. Meanwhile, residue Ala157, identified as a major 
contributor to  the enhanced affinity, was  also  uncovered to  form  strong hydrogen bonds  with the 
receptor  (2.10  Å,  157.2° ;  1.80  Å,  142.5° ;  2.23  Å,  166.6° ).  For  this  reason,  it  provided  stable 
interactions of inhibitors with the surrounding environment. In addition, for the class of SNS-314, only 
three hydrogen bonds  were  formed between the active binding site of the target  receptor and the 
docked compound 105. As depicted in Figure 5C, Ala157 (2.01 Å, 163.3° ; 2.08 Å, 161.7° ) and Leu83 
(1.76 Å, 146.3° ) were involved in the hydrogen bonding contacts with compound 105, possessing a 
further stabilization between the ligand and the receptor. 
Figure  6.  Stereoview  of  the  docked  conformations  of  compounds  25,  40  and  105, 
respectively, in the active site of Aurora B kinase. The hydrogen bonds are shown  by 
broken lines. Compounds 25, 40 and 105, colored purple, cyan and orange, are presented in 
pictures a, b and c, respectively. The important amino acid residues, Lys106, Ala157 and 
Glu161 (stick rendering) are colored by atom type (C, yellow; N, blue; H, white; O, red).  
 
Interestingly, two common active  amino  acid  residues were found  among the three classes  (as 
shown in Figure 6). Lys106 residue was found to possess hydrogen bonding interactions with both the 
inhibitors  (compounds  25  and  40),  respectively,  whereas,  compounds  40  and  105  both  presented 
Ala157 as an active amino acid residue. Therefore, it can be reasonably presumed that Ala157 and 
Lys106  are  considered  to  be  vital  amino  acids  that  have  great  effects  on  the  ligand-receptor Int. J. Mol. Sci. 2010, 11                       
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interactions of Aurora B kinase. Therefore, it may possibly account for the overall higher inhibitory 
activities of GSK1070916 class than the MK-0457 and SNS-314 classes. The most potent inhibitor of 
GSK1070916 derivatives (compound 40) has more hydrogen bonding interactions with both Ala157 
and Lys106 residues and thus is more active than the other two inhibitors (compounds 25 and 105)  
that  do  not.  Additionally,  the  docking  study  also  revealed  the  importance  of  the  amino  acid  
esidue,  Glu161,  which  possesses  strong  electrostatic  repulsion  interactions  with  all  the  three  
potency inhibitors. 
4. Conclusions  
The 3D-QSAR studies yielded stable and statistically significant predictive models with relative 
high cross-correlation coefficients for predicting the activities of new Aurora B inhibitors. A high 
LOOCV r
2 value and a small standard deviation indicate the existence of a similar relationship in all 
compounds of the series used in the study. The overall study for the optimal model from the MK-0457 
class  implies  the  crucial  roles  of  steric  and  electrostatic  field  effects,  while  the  GSK1070916  
model  revealed  the  importance  of  electrostatic  and  hydrogen-bond  donor  fields.  In  addition,  for  
SNS-314, hydrophobic and hydrogen-bond donor fields were found to be more important than the  
other descriptors. 
Satisfyingly,  a  good  correlation  was  attained  between  the  3D-QSAR  contour  maps  and  the 
corresponding predictive binding mode. For the MK-0457 model, the bulky substituent of –R2 group 
plays a main contribution toward the inhibitory activity, which is consistent with the existence of a 
wide steric gorge enclosing this group. In addition, the carbonyl group at 1-position is critical for the 
increase in the inhibitory activity. For GSK1070916 compounds, the preference for electronegative 
groups with hydrogen bond donating capacity at 2-position and –R1 group shows a great impact on the 
overall inhibitory activities. The model for SNS-314 revealed the hydrophobic favorable property at 
the –R3 group, which is consistent with the docking results. And the docking analysis demonstrated the 
importance of Glu161, Ala157 and Lys106 in facilitating Aurora B recognition of its inhibitors.  
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